- Determinants of developing post-vaccination side-effects among study participants.
| Factors | Yes | No | P-value | ||
|---|---|---|---|---|---|
| n | (%) | n | (%) | ||
| Age in years | |||||
| 18-25 | 1081 | (89.2) | 131 | (10.8) | 0.017* |
| 26-35 | 615 | (87.5) | 88 | (12.5) | |
| 36-50 | 413 | (83.1) | 84 | (16.9) | |
| 51-60 | 77 | (88.5) | 10 | (11.5) | |
| >60 | 27 | (87.1) | 4 | (12.9) | |
| Gender | |||||
| Male | 897 | (86.5) | 140 | (13.5) | 0.219 |
| Female | 1316 | (88.1) | 177 | (11.9) | |
| Nationality | |||||
| Saudi | 2097 | (87.2) | 309 | (12.8) | 0.036* |
| Non-Saudi | 116 | (93.5) | 8 | (6.5) | |
| Body mass index | |||||
| Non obese | 1211 | (86.9) | 183 | (13.1) | 0.314 |
| Overweight / obese | 1002 | (88.2) | 134 | (11.8) | |
| Educational level | |||||
| Below university | 456 | (76.9) | 137 | (23.1) | 0.001* |
| University | 1757 | (90.7) | 180 | (9.3) | |
| Work | |||||
| HCWs | 606 | (89.5) | 71 | (10.5) | .061 |
| Others | 1607 | (86.7) | 246 | (13.3) | |
| Smoking | |||||
| Yes | 384 | (93.2) | 28 | (6.8) | 0.001* |
| No | 1829 | (86.4) | 289 | (13.6) | |
| Chronic health problems | |||||
| Yes | 332 | (89.2) | 40 | (10.8) | 0.262 |
| No | 1881 | (87.2) | 277 | (12.8) | |
| Had any type of allergy | |||||
| Yes | 325 | (88.8) | 41 | (11.2) | 0.407 |
| No | 1888 | (87.2) | 276 | (12.8) | |
| Previously had positive test for COVID-19 | |||||
| Yes | 401 | (82.2) | 87 | (17.8) | 0.001* |
| No | 1812 | (88.7) | 230 | (11.3) | |
| Type of vaccine | |||||
| Pfizer | 1589 | (85.1) | 279 | (14.9) | 0.001* |
| AstraZeneca | 624 | (94.3) | 38 | (5.7) | |
| Infected with covid-19 after vaccination | |||||
| After 1st dose | 121 | (91.7) | 11 | (8.3) | 0.288# |
| After 2nd dose | 15 | (83.3) | 3 | (16.7) | |
| No | 2077 | (87.3) | 303 | (12.7) | |
P: Pearson X2 test, #: exact probability test, *p<0.05 (significant)